William Blair analyst Ryan Daniels has maintained their bullish stance on DOCS stock, giving a Buy rating on October 29.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ryan Daniels has given his Buy rating due to a combination of factors that highlight Doximity’s strong financial performance and strategic positioning. The company reported impressive revenue growth of 23% year-over-year, surpassing both consensus expectations and its own guidance. Additionally, Doximity’s adjusted EBITDA significantly exceeded forecasts, demonstrating robust profitability.
New bookings have shown strength, particularly with the company’s multimodal integrated offerings, which have increased annual sales visibility. The client portal is also gaining momentum, especially among small and medium-sized businesses, with a substantial increase in customer numbers. Despite some caution regarding potential challenges in pharma ad spending, Doximity’s management has raised its guidance for 2026, reflecting confidence in its digital solutions. These factors collectively support the Buy recommendation, suggesting that investors should consider accumulating shares, especially during market pullbacks.
In another report released on October 29, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $77.00 price target.